Utility of 18F-FDG PET/CT in medical care of a promyelocytic sarcoma.

Autor: Jacquet-Francillon N; Department of Nuclear Medicine, University Hospital, Saint-Etienne, France. Electronic address: nicolas.jacquetfrancillon@gmail.com., Cornillon J; Lucien-Neuwirth Institute of Cancerology, Clinical Hematology Department, Saint-Priest-en-Jarez, France. Electronic address: jerome.cornillon@icloire.fr., Flandrin P; Hematology Laboratory, University Hospital, Saint-Etienne, France. Electronic address: flandrin-gresta@chu-st-etienne.fr., Rigollet L; Cytology Laboratory, University Hospital, Saint-Etienne, France. Electronic address: lauren.rigollet@chu-st-etienne.fr., Prevot N; Department of Nuclear Medicine, University Hospital, Saint-Etienne, France. Electronic address: nathalie.prevot@chu-st-etienne.fr., Tavernier E; Lucien-Neuwirth Institute of Cancerology, Clinical Hematology Department, Saint-Priest-en-Jarez, France. Electronic address: emmanuelle.tavernier@icloire.fr., Bonnefoy PB; Department of Nuclear Medicine, University Hospital, Saint-Etienne, France. Electronic address: pierre.benoit.bonnefoy@gmail.com.
Jazyk: angličtina
Zdroj: Current research in translational medicine [Curr Res Transl Med] 2021 May; Vol. 69 (2), pp. 103272. Date of Electronic Publication: 2021 Jan 18.
DOI: 10.1016/j.retram.2020.103272
Abstrakt: Promyelocytic sarcoma is an uncommon solid tumor made up of myeloblasts. It is characterized, like acute promyelocytic leukemia (APL), by a chromosomal translocation t(15;17) involving the retinoic acid receptor alpha (RARalpha) and the promyelocytic gene (PML). The diagnosis and monitoring of promyelocytic sarcoma is a challenge due to the rarity and severity of the disease. We describe a case with several initial sites and without APL. The patient was monitored with regular 18F-FDG PET/CT from diagnosis to complete response. The evolution of PET/CT imageries was compared to the quantification of PML-RARα fusion gene by RQ-PCR. In promyelocytic sarcoma medical care, 18F-FDG PET/CT appears to be an attractive tool for finding targets for biopsy, for the primary staging, for assessing therapeutic response and for detecting early relapse.
(Copyright © 2020. Published by Elsevier Masson SAS.)
Databáze: MEDLINE
Externí odkaz: